samedan logo
 
 
spacer
home > pmps > winter 2002 > containment solutions: solids charging into process vessels
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Containment Solutions: Solids Charging into Process Vessels

Vessel charging in the process plant has long been identified as a major source of dust emission. Now, with increasing use of active pharmaceutical ingredients (APIs) in the processing and manufacturing stages, the need for assured operator protection is increasing the requirement for effective dust containment. The maximum permissible operator exposure level (OEL) considered in this article is 10g/m3.

What are the Available Options?

Containment during vessel charging falls into two key categories:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Martyn Ryder, Managing Director of Extract Technology
Martyn Ryder is the Managing Director of Extract Technology, part of the Carlisle Life Science Group. He was educated at Leeds Polytechnic in HVAC and Building Services.

In 1981 he founded Extract Technology, a supplier of pharmaceutical dust control and high containment systems, based in Huddersfield, UK.

spacer
Martyn Ryder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

FUJIFILM Irvine Scientific Begins Customer Qualification of European Manufacturing Facility

SANTA ANA, California, September 29, 2021: FUJIFILM Irvine Scientific, Inc., today announced that it completed construction and started the commissioning phase of its new manufacturing facility in Tilburg, the Netherlands. The commissioning milestone marks the beginning of validating the facility and equipment in anticipation of full operations starting in late 2021.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement